Orion Oyj (HEL:ORNAV)

Market Cap	7.66B
Revenue (ttm)	1.59B
Net Income (ttm)	347.40M
Shares Out	n/a
EPS (ttm)	2.47
PE Ratio	22.05
Forward PE	19.05
Dividend	1.64 (3.03%)
Ex-Dividend Date	Oct 15, 2025

Volume	8,916
Average Volume	7,717
Open	54.10
Previous Close	54.50
Day's Range	51.60 - 54.20
52-Week Range	36.50 - 56.90
Beta	0.43
RSI	46.25
Earnings Date	Apr 23, 2025

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Trexan for rheumatoid art...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1917
• Employees: 3,880
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: ORNAV

Financial Performance

In 2024, Orion Oyj's revenue was 1.54 billion, an increase of 29.65% compared to the previous year's 1.19 billion. Earnings were 329.90 million, an increase of 52.17%.